Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context

Segges, Priscilla; Braggio, Esteban; Minnicelli, Carolina; Hassan, Rocı́o; Zalcberg, Ilana; Maiolino, Ângelo

doi:10.1590/1414-431x20155034

Cited by 9 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 In the present study, chromosome abnormalities were identi ed in 56.3% (126/224) of MM patients using FICTION, similar to that reported (53%-69%) in previous studies. 10,11 The detection rate of cytogenetic abnormalities with FICTION was signi cantly higher than direct FISH of 36.6% (52/142) shown in this study. However, FICTION requires an additional laborious cytomorphologic selection process of plasma cells, which are frequently interfered with by background signals overlapping target signals.…”

Section: Discussioncontrasting

confidence: 56%

Cytogenetic Testing by Fluorescence in Situ Hybridization Is Improved by Plasma Cell Sorting in Multiple Myeloma

Cho

Lee

et al. 2021

Preprint

View full text Add to dashboard Cite

Accurate detection of cytogenetic abnormalities has become more important for improving risk-adapted treatment strategies in multiple myeloma (MM). However, precise cytogenetic testing by fluorescence in situ hybridization (FISH) is challenged by the dilution effect of bone marrow specimens and poor growth of plasma cells ex vivo. To address these issues, we compared the performances of three different enrichment modalities for FISH: direct FISH, fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) technique, and a plasma cell sorting FISH with fluorescence-activated cell sorter (FACS). We examined cytogenetic abnormalities in bone marrow cells of 493 patients with newly diagnosed MM and compared the efficacy of each modality. FISH disclosed cytogenetic abnormalities in 38.0% of samples by direct FISH, 56.3% by FICTION, and 95.5% by FACS-FISH, and the percentage of cells with abnormal signals detected by FISH was higher by FACS-FISH than direct FISH or FICTION. Our results suggest that the efficacy of FISH is dependent on the plasma cell enrichment modalities and reveal that plasma cell sorting FISH with FACS enables better detection of cytogenetic abnormalities in diagnostic MM samples with low plasma cell frequency.

show abstract

Section: Discussioncontrasting

confidence: 56%

Cytogenetic Testing by Fluorescence in Situ Hybridization Is Improved by Plasma Cell Sorting in Multiple Myeloma

Cho

Lee

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…12 In the present study, chromosome abnormalities were identified in 56.3% (126/224) of MM patients using FICTION, similar to that reported (53%-69%) in previous studies. 13,14 The detection rate of cytogenetic abnormalities with FICTION was significantly higher than direct FISH of 36.6% (52/142) shown in this study. However, FICTION requires an additional laborious cytomorphologic selection process of plasma cells, which are frequently interfered with by background signals overlapping target signals.…”

Section: Discussioncontrasting

confidence: 55%

Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma

Cho²,

Lee³

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Accurate detection of cytogenetic abnormalities has become more important for improving risk-adapted treatment strategies in multiple myeloma (MM). However, precise cytogenetic testing by fluorescence in situ hybridization (FISH) is challenged by the dilution effect of bone marrow specimens and poor growth of plasma cells ex vivo. It has been suggested that FISH should be performed in combination with plasma cell enrichment strategies. We examined cytogenetic abnormalities in newly diagnosed MM and compared the efficacy of three different enrichment modalities for FISH: direct FISH (n = 137), fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) technique (n = 224), and a plasma cell sorting FISH with fluorescence-activated cell sorter (FACS) (n = 132). FISH disclosed cytogenetic abnormalities in 38.0% of samples by direct FISH, 56.3% by FICTION, and 95.5% by FACS-FISH, and the percentage of cells with abnormal signals detected by FISH was significantly higher by FACS-FISH than direct FISH or FICTION. Our results suggest that the efficacy of FISH is dependent on the plasma cell enrichment modalities and reveal that plasma cell sorting FISH with FACS enables better detection of cytogenetic abnormalities in diagnostic MM samples.

show abstract

“…With the rapid changes of treatment pattern, the role of prognostic factors for MM has to be reevaluated accordingly. Among MM patients, about 16-24% can be detected with translocation t(11;14)(q13;q32), which ranks with the most common chromosomal translocation (1)(2)(3)(4)(5). Two decades ago, with or without consolidation by ASCT, MM patients with t (11;14) were classified into standard risk, which was supported by some studies (1,3,6,7).…”

Section: Introductionmentioning

confidence: 84%

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?

Gao

Liu

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Objective: To investigate the prognostic value of t(11;14) for de novo multiple myeloma (MM) patients in novel agent era. Methods: A total of 455 patients with fluorescence in situ hybridization (FISH), before treatments from three hospitals in China, were included in the study. All patients received autologous stem cell transplantation (ASCT) after induction therapy as consolidation. High risk (HR) cytogenetics were defined as t(4;14), t(14;16), and/or del 17p. Results: A total of 152 patients were in the HR group. Of patients without HR cytogenetics, 55 were in the t(11;14) group, and 248 were in the standard risk (SR) group without t(11;14). Gain in 1q21 was observed in 38.9% patients with t(11;14). There were no differences in median progression free survival (PFS) and overall survival (OS), respectively, between patients in the t(11;14) group and those in the SR group. Patients in the t(11;14) group had the longer median PFS and OS, respectively, compared with those in the HR group. Regardless of coexisting with 1q21 gain or not, patients in the t(11;14) group still had similar median PFS and OS compared to those in the SR group. Finally, multivariate analysis indicated that including 1q21 gain and bone marrow plasma cell with CD20 expression, no variables were found to predict the outcome of the t(11;14) group in our cohort. Conclusions: These results confirm that outcomes of t(11;14) MM are similar to standard risk patients when they receive novel agent induction therapy consolidated by ASCT. Gain of 1q21 coexists with t(11;14) frequently. In addition, both bone marrow plasma cell with CD20 expression and 1q21 gain have no impact on median PFS or OS for patients with t(11;14).

show abstract

Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context

Cited by 9 publications

References 21 publications

Cytogenetic Testing by Fluorescence in Situ Hybridization Is Improved by Plasma Cell Sorting in Multiple Myeloma

Cytogenetic Testing by Fluorescence in Situ Hybridization Is Improved by Plasma Cell Sorting in Multiple Myeloma

Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?

Contact Info

Product

Resources

About